Document Detail


Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
MedLine Citation:
PMID:  9329583     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The value of Prostate-Specific Antigen (PSA) for the early detection of Prostate Cancer (CaP) is controversial due to an appreciable false positive rate causing unnecessary biopsies. As PSA exits in both free and bound forms the percentage of free PSA was found to be lower in CaP than in Benign Prostatic Hyperplasia (BPH). We investigated whether the percentage of free PSA offers better discrimination on the detection of CaP. MATERIAL AND METHODS: In a retrospective analysis the percentage of free PSA was determined in the sera of 50 consecutive patients with histologically proven BPH (n = 30) and clinically localised CaP without metastases (n = 20; pT1-3 No Mo). Serum levels of free PSA and total PSA were determined employing a chemiluminescent enzyme immunoassay. RESULTS: Patients with CaP demonstrated a lower percentage of free PSA (median: 8.5, range: 2.7-24.5) than patients with BPH (median: 22.35, range: 8.9-66.7). (p < 0.001). CONCLUSION: Determination of percentage of free PSA enhances the discrimination between BPH and CaP and may reduce the number of unnecessary biopsies in patients with elevated PSA.
Authors:
J M Wolff; W Boeckmann; P J Effert; F K Habib; G Jakse
Related Documents :
14983963 - The clinical significance of a small focus of well-differentiated carcinoma at prostate...
12767363 - Prognostic factors and survival in node-positive (n1) prostate cancer-a prospective stu...
23605083 - A phase i trial of the igf-1r antibody cixutumumab in combination with temsirolimus in ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  17     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    1997 Jul-Aug
Date Detail:
Created Date:  1997-10-29     Completed Date:  1997-10-29     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  GREECE    
Other Details:
Languages:  eng     Pagination:  2993-4     Citation Subset:  IM    
Affiliation:
Department of Urology, RWTH Aachen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Diagnosis, Differential
Humans
Male
Prostate-Specific Antigen / blood*
Prostatic Hyperplasia / diagnosis*
Prostatic Neoplasms / diagnosis*
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The ratio of free to total prostate specific antigen: an advantageous addition in the differential d...
Next Document:  Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphatase.